Business
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.
About this update from Cytosorbents Corporation
[{"type":"list","items":[{"val":[{"type":"text","content":"2024 marked by strong commercial execution and improved operating leverage","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 ","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheet","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications ","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company has now adopted the standard accounting convention of reporting Revenue to only include Product Sales. Grant Income is no longer reported as a component of Revenue","length":175,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":564,"olType":false},{"type":"text","content":"PRINCETON, N.J., March 31, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.","length":350,"tagName":"p"},{"type":"image","alt":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents’ flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation)","displaySize":"","headline":null,"caption":"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents’ flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation)","className":"","disableSlideshowImg":false...